SCHEMBL4200539

SCHEMBL4200539

COCOc1cc(F)ccc1C(C)=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 5/20 0.48
MAOA P21397 2/20 0.48
FFAR4 Q5NUL3 1/20 0.44
SMN1; SMN2 Q16637 4/20 0.42
LMNA P02545 2/20 0.42
ALDH1A1 P00352 5/20 0.42
KMT2A Q03164 2/20 0.42
GAA P10253 1/20 0.42
KDM4E B2RXH2 1/20 0.41
CYP3A4 P08684 2/20 0.41
TSHR P16473 1/20 0.41
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
MAPT P10636 2/20 0.40
POLB P06746 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
PTPN1 P18031 1/20 0.40
HPGD P15428 1/20 0.40
MAPK1 P28482 1/20 0.40
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL187037 0.86 FFAR4 (0.59) FFAR4SMN1; SMN2ALDH1A1KMT2AKDM4E
SCHEMBL3846283 0.86 LMNA (0.51) MAOBMAOAFFAR4SMN1; SMN2LMNA
SCHEMBL4203948 0.84 MAPT (0.47) MAOBMAOAFFAR4SMN1; SMN2LMNA
SCHEMBL30628273 0.83 CYP3A4 (0.61) MAOBMAOAFFAR4SMN1; SMN2LMNA
SCHEMBL5445458 0.83 KDM4E (0.49) MAOBMAOAALDH1A1KMT2AKDM4E
SCHEMBL31088170 0.83 KDM4E (0.49) MAOBMAOAALDH1A1KMT2AKDM4E
SCHEMBL4271221 0.83 CYP3A4 (0.61) MAOBMAOAFFAR4SMN1; SMN2LMNA
SCHEMBL30785087 0.83 NPC1 (0.48) FFAR4SMN1; SMN2LMNAALDH1A1KMT2A
SCHEMBL4215199 0.82 ALDH1A1 (0.57) SMN1; SMN2LMNAALDH1A1KMT2ACYP3A4
SCHEMBL186911 0.82 TSHR (0.49) FFAR4SMN1; SMN2LMNAKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090156646-A1 PYRIDYLPHENOL COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed
EP-1921066-A1 PYRIDYLPHENOL COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2008-05-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156646-A1 PYRIDYLPHENOL COMPOUND AND USE THEREOF GNRHR, PGR, MC1R MAOB 1348/4885MAOA 1641/4885FFAR4 1472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.